LDA-induced small intestinal mucosal injury
Conditions
Interventions
The subjects in group A received LDA (100 mg) once daily.
The subjects in group B received LDA and 4.0 g of ES (1.0 g four times daily).
Sponsors
Osaka medical college
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) freely provided informed consent on the basis of their full understanding of the study protocol, and 2) had no history of medication use during the month before enrolment in the study
Exclusion criteria
Exclusion criteria: 1) history of peptic ulcer or gastrointestinal bleeding; 2) significant hepatic, renal, heart, or respiratory disease; 3) history of gastrointestinal surgery other than appendectomy; 4) use of oral histamine H2-receptor antagonists, gastrointestinal kinetic agents, and gastric mucoprotective drugs within 2 weeks before the study; 5) use of oral non-steroidal anti-inflammatory drugs (NSAIDs), steroids, anticholinergic drugs, anticancer drugs, or antithrombotic drugs within 4 weeks prior; 6) alcohol or chemical dependency; 7) history of gastrointestinal obstruction; 8) refusal to consent to the surgery that would be required if the capsule endoscope was retained in the body; and 9) determination by the investigator, at his/her discretion, that a subject was ineligible for participation in the study for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of small intestinal mucosal injury using small bowel capsule endoscopy | — |
Countries
Japan
Contacts
Public ContactKazuhiro Ota
Osaka medical college Second department of internal medicine
Outcome results
None listed